相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-gamma induced PD-L1 expression
Samir Mehndiratta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug
Jingkao Chen et al.
INVESTIGATIONAL NEW DRUGS (2020)
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair
Bin Deng et al.
DNA AND CELL BIOLOGY (2020)
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors, with potent in vitro and in vivo anticancer activity
Chunhui Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response
Wei-Cheng Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide
Ying Wu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
Ashish Thakur et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents
Gaoliang Cheng et al.
BIOORGANIC CHEMISTRY (2019)
An Overview of HDAC Inhibitors and their Synthetic Routes
Xiaopeng Peng et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
Xuewu Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro
Shuangxi Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases
Kehui Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2
Yu Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors
Aixin Geng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors
Baolei Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy
Zigao Yuan et al.
BIOORGANIC CHEMISTRY (2019)
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma
Ruolan Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
Bastian von Tresckow et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Mei-Jung Lai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy
Yong Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery
Wei Chen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm
Anthony F. Palermo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors
Mitsuaki Yamashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors
Jiwei Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold
Jian Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)
Lianbin Yao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma
Yuqin Zhang et al.
BMC CANCER (2018)
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC
Ritu Ojha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors
Sandra Atlante et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors
Raffaella Cincinelli et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma
Dizhong Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections
Yahui Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
Jie Zang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4
Diana Lamaa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer
Krikor Bijian et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer
Heba M. Hesham et al.
MEDICINAL RESEARCH REVIEWS (2018)
Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties
Rui Xie et al.
MEDCHEMCOMM (2018)
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
Kun Fang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera et al.
FRONTIERS IN ONCOLOGY (2018)
Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat
Yu-yi Chu-Farseeva et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
Raffaella Cincinelli et al.
PLOS ONE (2018)
Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy
Yingchao Duan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor
Sanil Bhatia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The emerging role of serum/glucocorticoid-regulated kinases in cancer
Pau Castel et al.
CELL CYCLE (2017)
Vitamin D receptor as a target for breast cancer therapy
Alyson Murray et al.
ENDOCRINE-RELATED CANCER (2017)
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment
Ying-Chao Duan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1
Zichen Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors
Guoqiang Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
Lianbin Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives
Dong Lu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors
Lanlan Zang et al.
ONCOTARGET (2017)
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells
Yin Li et al.
CLINICAL EPIGENETICS (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity
Rui Xie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors
Mingfeng Shao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Zigao Yuan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285
Chao Ding et al.
CHINESE CHEMICAL LETTERS (2017)
Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase
Idris Raji et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies
Dany Pechalrieu et al.
BIOCHEMICAL PHARMACOLOGY (2017)
The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101
Thomas Mehrling et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
Inhibitors of histone deacetylase as antitumor agents: A critical review
Mohammed Manal et al.
BIOORGANIC CHEMISTRY (2016)
Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors
Jie Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC
Fan-Wei Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells
Yi Liao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
Eugene Guorong Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Ten years of anti-vascular endothelial growth factor therapy
Napoleone Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Yves Pommier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Sherri Z. Millis et al.
JAMA ONCOLOGY (2016)
Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition
Jing Ma et al.
SCIENTIFIC REPORTS (2016)
Perspectives in the development of hybrid bifunctional antitumour agents
Loana Musso et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase
Fan-Wei Peng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer
Jian Geng et al.
CANCER LETTERS (2015)
Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase/ERK-MMP-laminin52 signaling pathway
Xiao Liu et al.
CANCER SCIENCE (2015)
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Thomas J. Galloway et al.
CLINICAL CANCER RESEARCH (2015)
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids
Quaovi H. Sodji et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
Min-Wu Chao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
Peter Bai
MOLECULAR CELL (2015)
Epigenetic modifications of histone H3 during the transdifferentiation of Thy-1(+) Lin(-) bone marrow cells into hepatocytes
Xinxin Liao et al.
MOLECULAR MEDICINE REPORTS (2015)
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal et al.
MOLECULES (2015)
Homocysteine Induces Collagen I Expression by Downregulating Histone Methyltransferase G9a
Wenjing Lei et al.
PLOS ONE (2015)
Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling
Shun Li et al.
TUMOR BIOLOGY (2015)
Effect of HDAC-6 on PD cell induced by lactacystin
Li-Fei Xing et al.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE (2015)
Functional role of G9a histone methyltransferase in cancer
Francesco Casciello et al.
FRONTIERS IN IMMUNOLOGY (2015)
DNA Methyltransferase 1/3a Overexpression in Sporadic Breast Cancer is Associated with Reduced Expression of Estrogen Receptor-Alpha/Breast Cancer Susceptibility Gene 1 and Poor Prognosis
Zhaojin Yu et al.
MOLECULAR CARCINOGENESIS (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy
Lei Zhang et al.
MEDICINAL RESEARCH REVIEWS (2015)
Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and can be inhibited by panobinostat
C. L. Wang et al.
NEOPLASMA (2015)
Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors
Nan Zhou et al.
DRUG DISCOVERIES AND THERAPEUTICS (2015)
TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma
Shuai Shuai et al.
CANCER LETTERS (2014)
VEGF Signal System: The Application of Antiangiogenesis
Xuewu Liang et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment
Konstantinos A. Papavassiliou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
The methyltransferase G9a regulates HoxA9-dependent transcription in AML
Bernhard Lehnertz et al.
GENES & DEVELOPMENT (2014)
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis
Kuo-Tai Hua et al.
MOLECULAR CANCER (2014)
The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
Shalome A. Bassett et al.
NUTRIENTS (2014)
Drugging Topoisomerases: Lessons and Challenges
Yves Pommier
ACS CHEMICAL BIOLOGY (2013)
Dual-acting histone deacetylase-topoisomerase I inhibitors
William Guerrant et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
Stacey M. Frumm et al.
CHEMISTRY & BIOLOGY (2013)
Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3
Fanliang Meng et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
Craig S. Takeuchi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment
Jhih-Bin Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Nicola J. Curtin et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Metabolic targets for cancer therapy
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
Eva Juengel et al.
PLOS ONE (2013)
Tamoxifen Resistance in Breast Cancer
Minsun Chang
BIOMOLECULES & THERAPEUTICS (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications
Ana Custodio et al.
CANCER TREATMENT REVIEWS (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Changgeng Qian et al.
CLINICAL CANCER RESEARCH (2012)
Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries
Takayoshi Suzuki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors
Francesca Musumeci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Conjugate of Pt(IV)-Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy
Jun Yang et al.
MOLECULAR PHARMACEUTICS (2012)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Entinostat for treatment of solid tumors and hematologic malignancies
Jeffrey Knipstein et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers
Shinya Hayami et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
Valentina Zuco et al.
PLOS ONE (2011)
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
Monica Galli et al.
ANNALS OF HEMATOLOGY (2010)
Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer
Viraj B. Gandhi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Paul A. Marks
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
Antonio Macchiarulo et al.
AMINO ACIDS (2009)
The Double-Edged Sword of Autophagy Modulation in Cancer
Eileen White et al.
CLINICAL CANCER RESEARCH (2009)
Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
Shuang Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway
A. Hrzenjak et al.
JOURNAL OF PATHOLOGY (2008)
DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines
J. Devon Roll et al.
MOLECULAR CANCER (2008)
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells
Leslie Hodges-Gallagher et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Targeting nitric oxide for cancer therapy
David Hirst et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Targeting the c-Met signaling pathway in cancer
Benedetta Peruzzi et al.
CLINICAL CANCER RESEARCH (2006)
Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
AJ Wilson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma
HJ Park et al.
CANCER LETTERS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Nitric oxide as a regulator of inflammatory processes
JL Wallace
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2005)
MDM2 is a central node in the p53 pathway: 12 years and counting
GL Bond et al.
CURRENT CANCER DRUG TARGETS (2005)
Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer
K Halkidou et al.
PROSTATE (2004)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
YF Shao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
HDAC6 expression is correlated with better survival in breast cancer
ZH Zhang et al.
CLINICAL CANCER RESEARCH (2004)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
P Zhu et al.
CANCER CELL (2004)
COX-2 inhibitors in cancer treatment and prevention, a recent development
XC Xu
ANTI-CANCER DRUGS (2002)
Molecular cloning and characterization of a novel histone deacetylase HDAC10
AR Guardiola et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain
JJ Tong et al.
NUCLEIC ACIDS RESEARCH (2002)
Expression profile of histone deacetylase 1 in gastric cancer tissues
JH Choi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Transcriptional regulation in acute promyelocytic leukemia
RJ Lin et al.
ONCOGENE (2001)
Genomewide studies of histone deacetylase function in yeast
BE Bernstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
